<DOC>
	<DOCNO>NCT01748773</DOCNO>
	<brief_summary>This single arm , open-label study evaluate safety efficacy combination oxaliplatin , capecitabine Herceptin ( trastuzumab ) chemoradiotherapy adjuvant setting patient curatively resect HER2-positive gastric gastro-esophageal junction cancer . Patients receive Herceptin 8 mg/kg intravenously ( iv ) Day 1 Cycle 1 6 mg/kg iv Day 1 every follow 3-week cycle , oxaliplatin 100 mg/m2 iv Day 1 Cycles 1-3 capecitabine 850 mg/m2 orally twice daily Days 1-14 Cycles 1-3 5 day per week chemoradiotherapy . Radiotherapy give total dose 45 Gy divide 25 dos 5 treatment day week 5 week start Day 22 Cycle 3 . Anticipated time study treatment 1 year .</brief_summary>
	<brief_title>A Study Combination Oxaliplatin , Capecitabine Herceptin ( Trastuzumab ) Chemoradiotherapy The Adjuvant Setting Operated Patients With HER2+ Gastric Gastro-Esophageal Junction Cancer ( TOXAG Study )</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patient , 18 75 year age Curatively resect HER2positive gastric gastroesophageal junction adenocarcinoma ; HER2+ status define IHC2+ IHC3+ corroborative FISH+ result Patients Stage IB ( T1N1M0 ) disease high , except metastatic ( Stage IV ) disease Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 Left ventricular ejection fraction &gt; /= 50 % No know contraindication capecitabine , oxaliplatin trastuzumab No contraindication radiotherapy receive previous radiotherapy reason Previous neoadjuvant chemotherapy and/or radiotherapy Any disruption physical integrity upper gastrointestinal tract ( except surgical intervention gastric gastroesophageal junction carcinoma ) Known ( previously diagnose ongoing ) malabsorption syndrome Active gastrointestinal bleeding Any malignancy within past 5 year , except squamous cell carcinoma skin Clinically significant cardiac cardiovascular disease Uncontrolled hypertension Patients receive investigational anticancer treatment treat concomitant investigational drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>